Platelet Aggregation Inhibitors - Pharmacology
Research News and Information

Sunday, November 22, 2009

Discovery of novel protease activated receptors 1 antagonists with potent antithrombotic activity in vivo.

6 Oct 2009 Protease activated receptors (PARs) or thrombin receptors constitute a class of G-protein-coupled receptors (GPCRs) implicated in the activation of many physiological mechanisms. Thus, thrombin activates many cell types such as vascular smooth ... Read more...

Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal disease.

29 Sep 2009 OBJECTIVE: The pharmacokinetic (PK) and pharmacodynamic (PD) responses to prasugrel were compared in three studies of healthy subjects vs. those with moderate or end-stage renal impairment. METHODS: Two of the three protocols were parallel-design, ... Read more...

In vitro inhibition of factor XIII retards clot formation, reduces clot firmness, and increases fibrinolytic effects in whole blood.

29 Sep 2009 BACKGROUND: Thrombelastography has received renewed interest in the perioperative setting. The main determinants of thrombelastographic results are coagulation factor concentrations (various zymogens and fibrinogen) and platelet count; thus, ... Read more...

Latest indexed articles for 'Platelet Aggregation Inhibitors - Pharmacology'

These are the very latest articles for this heading:

• Discovery of novel protease activated receptors 1 antagonists with potent antithrombotic activity in vivo. 6 Oct 2009
• Hunting for the "sweet spot" in P2Y12 receptor blockade. 4 Oct 2009
• Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal disease. 29 Sep 2009
• In vitro inhibition of factor XIII retards clot formation, reduces clot firmness, and increases fibrinolytic effects in whole blood. 29 Sep 2009
• Antithrombotics in acute coronary syndromes. 6 Sep 2009
• Integrin priming dynamics: mechanisms of integrin antagonist-promoted alphaIIbbeta3:PAC-1 molecular recognition. 6 Sep 2009
• Prasugrel (Effient) vs. clopidogrel (Plavix). 5 Sep 2009
• New antiplatelet agents. 30 Aug 2009
• Is it safe to use a proton pump inhibitor with clopidogrel? 30 Aug 2009
• Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. 30 Aug 2009
• The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale. 30 Aug 2009
• Aspirin resistance. 30 Aug 2009
• Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. 24 Aug 2009
• Editorial comment. 12 Aug 2009
• Fibrin clot inhibitor medication and efficacy of bacillus Calmette-Guerin for bladder urothelial cancer. 12 Aug 2009
• Platelet reactivity and stent thrombosis: still some issues to solve. 9 Aug 2009
• Native platelet aggregation and response to aspirin in persons with the metabolic syndrome and its components. 30 Jul 2009
• Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjects. 30 Jul 2009
• Response to aspirin in healthy individuals. Cross-comparison of light transmission aggregometry, VerifyNow system, platelet count drop, thromboelastography (TEG) and urinary 11-dehydrothromboxane B(2). 30 Jul 2009
• Cross validation of the Multiple Electrode Aggregometry. A prospective trial in healthy volunteers. 30 Jul 2009

See a longer list of these articles.

Technical information about 'Platelet Aggregation Inhibitors'

Definition: Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.

Registry Number: 0

Descriptor UI: D010975

Alternative terms: Platelet Aggregation Inhibitors; Aggregation Inhibitors, Platelet; Inhibitors, Platelet Aggregation; Blood Platelet Antiaggregants; Antiaggregants, Blood Platelet; Platelet Antiaggregants; Antiaggregants, Platelet; Blood Platelet Aggregation Inhibitors; Platelet Inhibitors; Inhibitors, Platelet; Antiplatelet Agents; Agents, Antiplatelet; Antiplatelet Drugs; Drugs, Antiplatelet; Platelet Antagonists; Antagonists, Platelet; Blood Platelet Antagonists; Antagonists, Blood Platelet;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D27.505.954.502.780;

History Note: 88

Technical Notes: DF: PLATELET INHIB